RECENT PLACEMENT

Occam's AI Practice Expands with the Recruitment of Dr. Rajiv Patni as Strategic Clinical Advisor to BioXcel Therapeutics

Occam's AI Practice Expands with the Recruitment of Dr. Rajiv Patni as Strategic Clinical Advisor to BioXcel Therapeutics

In December 2023, Occam placed Dr. Rajiv Patni as Strategic Clinical Advisor to CEO Vimal Mehta and the Board of Directors at BioXcel Therapeutics.

Dr. Patni served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage firm recently acquired by Biogen. Prior to that, he experienced substantial success as CMO of multiple public small-cap, commercial-stage biopharma companies, including Adamas, Portola, and Global Blood Therapeutics.  He joined these companies at a turning point in their R&D growth trajectories and contributed to their acquisition by larger firms.  Earlier in his career, Dr. Patni had roles of increasing responsibility at Pfizer, Roche, and Actelion.

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.  Occam is a leader in recruiting artificial intelligence and machine learning talent for the life sciences, having partnered with insitro, Recursion, GSK, Atomic AI, Relation, Chemify, LabGenius, Nucleome, Charm Therapeutics, Anagenex, and ZebiAI. 

‍

Recent Placements

  1. Avirup Bose, Ph.D., as Chief Business Officer of Iktos
  2. Steve Harrison as CSO at Nucleome
  3. Aimee Einstein as VP of People & Culture at SI-BONE
  4. David Brower as CBO for Oncology Biotech Accent Therapeutics
  5. Annette Matthies as CBO at Elicio Therapeutics
  6. Steve Staben as CSO at Lycia Therapeutics
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.